The outcome of HBeAg to anti-HBe seroconversion is dual, depending upon the ability of the immune system to control HBV replication, and it can exit into HBeAg-negative infection without HBV-related liver disease or in HBeAg-negative CHB. Here, HBE1 is linked to infection.